We are truly glad to announce that BPI France granted GAOMA Therapeutics with a funding program of €2m, that will be dedicated to bring our first-in-class drug-candidate GAO-3-02 through regulatory preclinical development, up to completing a FiH Ph1 clinical trial application.
GAO-3-02 is the first derivative of synaptamide under development, with epilepsy and cognitive disorders as initial targeted indications.
This financing represents a first contribution to the next fund raising that GAOMA is currently preparing.
This funding, named Aide au Développement DeepTech (ADD), is a program financed by the French government in the context of the Programme d’Investissements d’Avenir.